Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
VEDANTA BIOSCIENCES, INC. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is handled by 1 distinct examiner, ARIANI, KADE. As the busiest examiner, ARIANI, KADE is responsible for 1 pending office action. This concentration means that the entirety of the company's current prosecution is subject to the review of this 1 individual. For the applicant, the outcome of the current cycle depends on the specific perspective of this examiner.
The portfolio is further localized within 1 distinct art unit. With only 1 distinct examiner and 1 distinct art unit involved, the prosecution is highly focused within the Biotechnology & Pharmaceuticals field. ARIANI, KADE has 1 pending office action, which matches the total count for the company. This alignment between the busiest examiner and the total pending actions suggests a narrow technical scope for the current applications. The absence of multiple examiners or art units means there is no internal data to compare examiner behavior for these 1 pending office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| No statute on record | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARIANI, KADE | 1 | 74.9% | +32.4% |
| IANNUZO, NATALIE NMN | 1 | 12.5% | +71.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17633930 | COMPOSITIONS AND METHODS FOR SUPPRESSING PATHOGENIC ORGANISMS | IANNUZO, NATALIE NMN | 26d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17633930 | COMPOSITIONS AND METHODS FOR SUPPRESSING PATHOGENIC ORGANISMS | IANNUZO, NATALIE NMN | 26d |
| 18574232 | METHODS OF COLONIZING A MICROBIOME, TREATING AND/OR PREVENTING INFLAMMATORY BOWEL DISEASE AND GRAFT VERSUS HOST DISEASE | ARIANI, KADE | — |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18574232 | METHODS OF COLONIZING A MICROBIOME, TREATING AND/OR PREVENTING INFLAMMATORY BOWEL DISEASE AND GRAFT VERSUS HOST DISEASE | ARIANI, KADE | 1651 | — | Non-Final OA | — | Pending | Dec 26, 2023 |
| 17633930 | COMPOSITIONS AND METHODS FOR SUPPRESSING PATHOGENIC ORGANISMS | IANNUZO, NATALIE NMN | 1653 | §103 | Final Rejection | 26d | Pending | Feb 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial